Scarica l'app Stockscreener
123.03
0.32%
0.39
Dopo l'orario di chiusura:
123.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$122.64
Aprire:
$122.88
Volume 24 ore:
1.02M
Relative Volume:
0.69
Capitalizzazione di mercato:
$12.18B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
41.71
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
+2.05%
1M Prestazione:
+15.56%
6M Prestazione:
-2.81%
1 anno Prestazione:
-12.42%
Intervallo 1D:
$122.47
$124.30
Intervallo di 1 settimana:
$117.59
$124.30
Portata 52W:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
123.03 | 11.93B | 2.41B | 305.80M | 492.20M | 2.95 |
|
HLN
Haleon Plc Adr
|
11.25 | 49.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
165.40 | 71.87B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.80 | 4.35M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.59 | 44.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.15 | 18.98B | 16.54B | -1.64B | 749.00M | -1.45 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - GlobeNewswire Inc.
Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com
Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - Yahoo Finance
Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia
How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com
Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq
Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com
Tourette Syndrome Treatment Market Detailed Analysis - openPR.com
Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus
Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa
Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia - Nasdaq
Neurocrine reports lasting benefits of CRENESSITY in CAH study By Investing.com - Investing.com India
Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures - marketscreener.com
Neurocrine reports quality of life gains in tardive dyskinesia study - Investing.com
Neurocrine reports progress for CAH drug as Voyager partnership shifts - The Pharma Letter
Neurocrine reports lasting benefits of CRENESSITY in CAH study - Investing.com
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting - PR Newswire
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia - WV News
Groundbreaking One-Year Data: New Drug Reduces Steroid Use in Children with Rare Hormone Disorder - Stock Titan
Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
90% Success Rate: CRENESSITY Shows Breakthrough Results in Congenital Adrenal Hyperplasia | NBIX Stock News - Stock Titan
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont) - PR Newswire
Neurocrine (NBIX) Highlights Risks of High Glucocorticoid Doses in CAH Patients | NBIX Stock News - GuruFocus
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results - Longview News-Journal
New Research Reveals Dangerous Side Effects of High-Dose Steroids in CAH Treatment: What Doctors Need to Know - Stock Titan
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Neurocrine at BofA Conference: Strategic Moves and Market Challenges - Investing.com
Learn to Evaluate (NBIX) using the Charts - news.stocktradersdaily.com
Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential - Insider Monkey
Neurocrine Biosciences To Present BofA Securities 2025 Health Care Conference; Webcast At 2:20 PM ET - Nasdaq
Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis - HCPLive
Cognitive Impairment Associated with Schizophrenia Pipeline - openPR.com
Cognitive Impairment Associated with Schizophrenia Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine - Barchart.com
Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality - Yahoo Finance
Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27% - simplywall.st
Wedbush Lifts Earnings Estimates for Neurocrine Biosciences - Defense World
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00 - Defense World
Wedbush Forecasts Lower Earnings for Neurocrine Biosciences - Defense World
Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Neurocrine leans on singer Carnie Wilson for tardive dyskinesia push - Medical Marketing and Media
Neurocrine Reports Late Stage Data Of Crenessity - marketscreener.com
Neurocrine Biosciences, Inc. Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst?? Pediatric Study - marketscreener.com
Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance - MSN
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target - Investing.com Australia
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.29%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):